AL-15469A for the Treatment of Bacterial Conjunctivitis
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Conjunctivitis
Intervention: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% (Drug); Moxifloxacin hydrochloride ophthalmic solution 0.5% as base (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Alcon Research
Summary
The purpose of the study is to determine whether AL-15469A is safe and effective in the
treatment of bacterial conjunctivitis.
Clinical Details
Official title: An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Clinical cure and microbiological success
Secondary outcome: Individual signs and symptoms of bacterial conjunctivitis at each visit
Eligibility
Minimum age: 1 Month.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- signs and symptoms of bacterial conjunctivitis
- Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- under 1 mo. age
- Other protocol-defined exclusion criteria may apply
Locations and Contacts
Contact Alcon for Trial Locations, Fort Worth, Texas 76134, United States
Additional Information
Starting date: May 2006
Last updated: March 1, 2012
|
